S&P 500   4,283.85
DOW   33,573.28
QQQ   354.84
High Dividend REITs: Are They an Ideal Way to Diversify?
Lithium Has Boomed And This American Stock Is Ready.. (Ad)
Dollar General May Create an Opportunity for Patient Investors
Is Frontline's 20% Dividend Too Good To Be True?
“Amazon Loophole” could hand you $28,544 in “royalty” payouts (Ad)
3 Reasons The Wayfair Rally Is Way Overdone
Wheat prices jump following collapse of major dam in southern Ukraine
Lithium Has Boomed And This American Stock Is Ready.. (Ad)
Here’s What’s Driving the Price of Carvana Higher
Stock market today: Asian stocks mixed as Wall St inches toward bull market
S&P 500   4,283.85
DOW   33,573.28
QQQ   354.84
High Dividend REITs: Are They an Ideal Way to Diversify?
Lithium Has Boomed And This American Stock Is Ready.. (Ad)
Dollar General May Create an Opportunity for Patient Investors
Is Frontline's 20% Dividend Too Good To Be True?
“Amazon Loophole” could hand you $28,544 in “royalty” payouts (Ad)
3 Reasons The Wayfair Rally Is Way Overdone
Wheat prices jump following collapse of major dam in southern Ukraine
Lithium Has Boomed And This American Stock Is Ready.. (Ad)
Here’s What’s Driving the Price of Carvana Higher
Stock market today: Asian stocks mixed as Wall St inches toward bull market
S&P 500   4,283.85
DOW   33,573.28
QQQ   354.84
High Dividend REITs: Are They an Ideal Way to Diversify?
Lithium Has Boomed And This American Stock Is Ready.. (Ad)
Dollar General May Create an Opportunity for Patient Investors
Is Frontline's 20% Dividend Too Good To Be True?
“Amazon Loophole” could hand you $28,544 in “royalty” payouts (Ad)
3 Reasons The Wayfair Rally Is Way Overdone
Wheat prices jump following collapse of major dam in southern Ukraine
Lithium Has Boomed And This American Stock Is Ready.. (Ad)
Here’s What’s Driving the Price of Carvana Higher
Stock market today: Asian stocks mixed as Wall St inches toward bull market
S&P 500   4,283.85
DOW   33,573.28
QQQ   354.84
High Dividend REITs: Are They an Ideal Way to Diversify?
Lithium Has Boomed And This American Stock Is Ready.. (Ad)
Dollar General May Create an Opportunity for Patient Investors
Is Frontline's 20% Dividend Too Good To Be True?
“Amazon Loophole” could hand you $28,544 in “royalty” payouts (Ad)
3 Reasons The Wayfair Rally Is Way Overdone
Wheat prices jump following collapse of major dam in southern Ukraine
Lithium Has Boomed And This American Stock Is Ready.. (Ad)
Here’s What’s Driving the Price of Carvana Higher
Stock market today: Asian stocks mixed as Wall St inches toward bull market
NASDAQ:JANX

Janux Therapeutics (JANX) Stock Forecast, Price & News

$13.75
-0.21 (-1.50%)
(As of 06/6/2023 ET)
Compare
Today's Range
$13.54
$14.26
50-Day Range
$11.08
$15.92
52-Week Range
$9.90
$23.64
Volume
226,521 shs
Average Volume
126,162 shs
Market Capitalization
$575.16 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$28.33

Janux Therapeutics MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
106.1% Upside
$28.33 Price Target
Short Interest
Bearish
12.78% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.81mentions of Janux Therapeutics in the last 14 days
Based on 3 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($2.35) to ($2.51) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.83 out of 5 stars

Medical Sector

663rd out of 981 stocks

Biotechnology Industry

26th out of 39 stocks


JANX stock logo

About Janux Therapeutics (NASDAQ:JANX) Stock

Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on proprietary Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms technology to treat patients suffering from cancer. Its lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth factor receptor, and trophoblast cell surface antigen 2. The company is also developing a TRACIr costimulatory bispecific product candidate against programmed death-ligand 1 and Cluster of Differentiation 28 designed to improve the anti-tumor activity of T cells. In addition, its PSMA-TRACTr is designed to target PSMA, a protein expressed in prostate cancer tumors and the vasculature of other tumors; EGFR-TRACTr is designed to target EGFR in various cancer types with multiple approved monoclonal antibodies; and TROP2-TRACTr is designed to target TROP2, a clinically validated anti-tumor target for which there is an approved anti-TROP2 antibody-drug conjugate. The company was incorporated in 2017 and is headquartered in San Diego, California.

Receive JANX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Janux Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

JANX Stock News Headlines

"Unknown laser company making HUGE profit from Russia-Ukraine War"
On February 24th, Russia invaded Ukraine. This caused major stock losses and soaring gas prices. But it also created a HUGE opportunity for savvy investors. There's an unknown laser company that's been profiting greatly from this war... ...and from another major conflict happening 3,000 miles away. Learn more here >>>
Janux Therapeutics (NASDAQ:JANX) Shares Up 8.3%
Janux Therapeutics, Inc. (NASDAQ:JANX) Short Interest Update
"Unknown laser company making HUGE profit from Russia-Ukraine War"
On February 24th, Russia invaded Ukraine. This caused major stock losses and soaring gas prices. But it also created a HUGE opportunity for savvy investors. There's an unknown laser company that's been profiting greatly from this war... ...and from another major conflict happening 3,000 miles away. Learn more here >>>
Janux Therapeutics (NASDAQ:JANX) Stock Price Down 5.6%
Janux Therapeutics (NASDAQ:JANX) Trading 3.5% Higher
Janux Therapeutics (NASDAQ:JANX) Stock Price Up 3.2%
Janux Therapeutics (NASDAQ:JANX) Trading 7.6% Higher
Janux Therapeutics (NASDAQ:JANX) Trading Up 4.6%
See More Headlines

JANX Price History

JANX Company Calendar

Last Earnings
3/10/2023
Today
6/06/2023
Next Earnings (Estimated)
8/08/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Biotechnology
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:JANX
Fax
N/A
Employees
62
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$28.33
High Stock Price Forecast
$35.00
Low Stock Price Forecast
$24.00
Forecasted Upside/Downside
+106.1%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

Net Income
$-63,060,000.00
Net Margins
-731.63%
Pretax Margin
-739.81%

Debt

Sales & Book Value

Annual Sales
$8.61 million
Book Value
$7.70 per share

Miscellaneous

Free Float
27,024,000
Market Cap
$575.16 million
Optionable
Not Optionable
Beta
1.53

Key Executives

  • Dr. David Alan Campbell Ph.D. (Age 63)
    Pres, CEO & Director
    Comp: $852.5k
  • Dr. Wayne Godfrey M.D. (Age 62)
    Chief Medical Officer
    Comp: $626.4k
  • Mr. Byron Robinson J.D. (Age 58)
    Ph.D., Chief Strategy Officer
    Comp: $606.8k
  • Mr. Tighe M. Reardon C.F.A. (Age 47)
    CPA, CPA, Acting Chief Financial Officer
  • Mr. Tommy Diraimondo Ph.D.
    Exec. Director of R&D
  • Mr. Charles M. Winter (Age 54)
    Chief Technical Officer
  • Mr. James Pennington
    Gen. Counsel
  • Ms. Brenda Van Vreeswyk
    Head of HR
  • Mr. Andy Hollman Meyer (Age 39)
    Chief Bus. Officer













JANX Stock - Frequently Asked Questions

Should I buy or sell Janux Therapeutics stock right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Janux Therapeutics in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" JANX shares.
View JANX analyst ratings
or view top-rated stocks.

What is Janux Therapeutics' stock price forecast for 2023?

3 analysts have issued 1 year target prices for Janux Therapeutics' shares. Their JANX share price forecasts range from $24.00 to $35.00. On average, they predict the company's stock price to reach $28.33 in the next year. This suggests a possible upside of 106.1% from the stock's current price.
View analysts price targets for JANX
or view top-rated stocks among Wall Street analysts.

How have JANX shares performed in 2023?

Janux Therapeutics' stock was trading at $13.17 at the beginning of the year. Since then, JANX stock has increased by 4.4% and is now trading at $13.75.
View the best growth stocks for 2023 here
.

When is Janux Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 8th 2023.
View our JANX earnings forecast
.

How were Janux Therapeutics' earnings last quarter?

Janux Therapeutics, Inc. (NASDAQ:JANX) released its quarterly earnings data on Friday, March, 10th. The company reported ($0.39) EPS for the quarter, topping the consensus estimate of ($0.45) by $0.06. The business had revenue of $2.85 million for the quarter, compared to the consensus estimate of $1.69 million. Janux Therapeutics had a negative net margin of 731.63% and a negative trailing twelve-month return on equity of 20.31%.

What ETFs hold Janux Therapeutics' stock?

ETFs with the largest weight of Janux Therapeutics (NASDAQ:JANX) stock in their portfolio include Loncar Cancer Immunotherapy ETF (CNCR),

When did Janux Therapeutics IPO?

(JANX) raised $152 million in an initial public offering on Friday, June 11th 2021. The company issued 9,500,000 shares at $15.00-$17.00 per share. BofA Securities, Cowen and Evercore ISI served as the underwriters for the IPO and H.C. Wainwright & Co. LLC was co-manager.

What is Janux Therapeutics' stock symbol?

Janux Therapeutics trades on the NASDAQ under the ticker symbol "JANX."

Who are Janux Therapeutics' major shareholders?

Janux Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include FMR LLC (12.29%), EcoR1 Capital LLC (9.18%), BVF Inc. IL (3.79%), BlackRock Inc. (2.71%), Geode Capital Management LLC (0.85%) and State Street Corp (0.71%). Insiders that own company stock include Corp Bregua and Orbimed Advisors Llc.

How do I buy shares of Janux Therapeutics?

Shares of JANX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Janux Therapeutics' stock price today?

One share of JANX stock can currently be purchased for approximately $13.75.

How much money does Janux Therapeutics make?

Janux Therapeutics (NASDAQ:JANX) has a market capitalization of $575.16 million and generates $8.61 million in revenue each year. The company earns $-63,060,000.00 in net income (profit) each year or ($1.62) on an earnings per share basis.

How can I contact Janux Therapeutics?

The official website for the company is www.januxrx.com. The company can be reached via phone at 858-751-4493 or via email at investors@janux.com.

This page (NASDAQ:JANX) was last updated on 6/7/2023 by MarketBeat.com Staff

My Account -